<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">IL-6 Receptor-Inhibiting Monoclonal Antibody that has been previously used in the treatment of Rheumatoid arthritis. It is currently being tested in more than fifteen registered trials targeted at managing the “cytokine storm” immune response in severely ill COVID-19 patients. Results from a recent Phase 3 trial showed that Sarilumab did not meet any of the primary or secondary endpoints of the study and is thus ineffective in COVID-19 patients requiring mechanical ventilation 
 <xref rid="b0355" ref-type="bibr">[71]</xref>.
</p>
